Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF29AZ
|
|||
| Drug Name |
Icosapent ethyl
|
|||
| Synonyms |
ICOSAPENT ETHYL; ethyl icosapentate; 86227-47-6; Eicosapentaenoic acid ethyl ester; ethyl eicosapentaenoate; Epadel; Vascepa; Timnodonic acid ethyl ester; EPA ethyl ester; ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate; AMR101; Ethyl icosapentate [JAN]; cis-Eicosapentaenoic acid ethyl ester; Ethyl eicosapentaenoic acid; Ethyl icosapent; AMR 101; Eicosapentaenoic acid, ethyl ester; Icosapent ethyl ester; E-EPA; Icosapent ethyl [USAN]; AMR-101; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester; UNII-6GC8A4PAYH; 6GC8A4PAYH; Ethyl (all cis)-5,8,11,14,17-icosapentaenoate; NSC-759597; ethyl all-cis-5,8,11,14,17-icosapentaenoate; 73310-10-8; Ethyl all cis-5,8,11,14,17-Eicosapentaenoate; Ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate; Ethyl all-cis-5,8,11,14,17-icosapentaenoic acid; CHEBI:80366; CHEBI:84883; all-cis-ethyl 5,8,11,14,17-icosapentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate; cis-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; NSC 759597; Icosapent ethyl (USAN); Ethyl all cis-5,8,11,14,17-Icosapentaenoate; ethyl icosapentaenoate; (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid ethyl ester; ethyl-eicosapentaenoic acid; ethyl-EPA; EICOSAPENTAENOIC ACID ETHYL ESTER (MART.); EICOSAPENTAENOIC ACID ETHYL ESTER (USP-RS); EICOSAPENTAENOIC ACID ETHYL ESTER [MART.]; EICOSAPENTAENOIC ACID ETHYL ESTER [USP-RS]; EPA-E; Vazkepa; Epadel S; Ethyl EPA; Vascepa (TN); Epadel S (TN); Ethyl icosapentate, JAN; Eicosapentaenoicacidethylester; Ethyl icosapentate (JP17); SCHEMBL123305; GTPL7441; MND 21; ICOSAPENT ETHYL [VANDF]; CHEMBL2095209; DTXSID601018686; HMS2094K19; Pharmakon1600-01300030; Eicosapentaenoic acid (ethyl ester); HY-B0747; LMFA07010877; MFCD00673476; NSC759597; s6466; ICOSAPENT ETHYL [ORANGE BOOK]; 5,8,11,14,17-eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)-; AKOS025295847; CCG-213714; CS-5304; DB08887; AC-33765; BS-48985; SBI-0206684.P002; E0442; E0853; EICOSAPENTAENOIC ACID ETHYL ESTER [MI]; D01892; AB01563352_01; EICOSAPENTAENOICACIDETHYLESTER(EPAEE)(SG); EICOSAPENTAENOIC ACID ETHYL ESTER [WHO-DD]; EN300-25951782; SR-05000002595; Q5404453; SR-05000002595-1; cis-5,8,11,14,17-Eicosapentaenoic acidethyl ester; (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, ethyl ester; 5-8-11-14-17-all cis-eicosapentaenoic acid ethyl ester; Ethyl ester(all-Z)-5,8,11,14,17-Eicosapentaenoic acid; 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-; 86227-47-6 for all ''Z'' compound, 73310-10-8 for ''undefined'' compound
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2/3 | [1] | |
| Company |
VA Office of Research and Development, University of Wisconsin, Madison
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H34O2
|
|||
| Canonical SMILES |
CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
|
|||
| InChI |
InChI=1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-
|
|||
| InChIKey |
SSQPWTVBQMWLSZ-AAQCHOMXSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02719327) Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.